Searched for
GENERIC OPHTHALMIC SOLUTION
For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 33%To get clarity on the markets, there are three questions to which you need answers. First: When will the war end? Second: How long will it ...
- Dr Reddy's launches generic OTC ophthalmic solution in US marketDr Reddy's Laboratories has launched a new eye drop in the United States. This over-the-counter solution treats itchy eyes. It is an antihi...
- Glenmark launches generic ophthalmic solution in US marketGlenmark Pharmaceuticals' subsidiary has introduced Latanoprost ophthalmic solution, a generic medication for glaucoma, in the US market. T...
- Glenmark launches generic glaucoma treatment ophthalmic solutionGlenmark Pharmaceuticals Inc., USA launched a generic version of Travatan Z, a glaucoma treatment, called Travoprost ophthalmic solution (0...
- Dr Reddy's, FDC recall products in US for manufacturing issuesDr Reddy's Laboratories and FDC Ltd issued voluntary recalls for medications in the US market due to manufacturing defects. Dr Reddy's reca...
- Alembic Pharma gets USFDA nod for generic Bromfenac ophthalmic solutionAlembic Pharmaceuticals Ltd has obtained final approval from the US FDA for its generic Bromfenac ophthalmic solution, used to treat postop...
- Lupin gets USFDA nod for Bromfenac Ophthalmic SolutionPharma major Lupin on Wednesday said it has received approval from the US health regulator to market its generic Bromfenac Ophthalmic Solut...
- Midcap stock zooms 9% on receiving USFDA approval for glaucoma drugBrimonidine Tartrate Ophthalmic Solution is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressu...
- Dr Reddy's Laboratories launches over-the-counter eye allergy drop in USDr Reddy's said Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2 per cent and 0.1 per cent, are indicated for the temporary relief of...
- Alembic gets USFDA nod for generic ophthalmic solutionAlembic Pharmaceuticals on Monday said it has received approval from the US health regulator to market Alcaftadine ophthalmic solution, in ...
- Alembic Pharma gets USFDA nod for 2 generic productsThe product is generic version of Sanofi-Aventis US LLC's Aubagio tablets in the same strengths.
- Local pharma formulators to benefit from new USFDA generic guidance: ReportThis will help domestic pharma formulators with pending ANDA approvals to reduce review cycles and expedite approvals, says a weekend repor...
- Lupin gains 4% on drug launch in USVigamox had US sales of USD 267.9 million (IMS MAT March 2017), the report added.
- Lupin launches generic conjunctivitis treatment medicine in USThe product is produced at Lupin's Pithampur manufacturing facility, it added. The medicine is generic equivalent of Novartis Corp's Vigamo...
- Sun Pharma gets USFDA nod for eye inflammation drugThe company is likely to commercialise BromSite through its newly formed US-based division Sun Ophthalmics in the second half of 2016.
- Aurobindo Pharma gets USFDA nod for its conjunctivitis drugAurobindo Pharma has received approval from the USFDA nod for generic Olopatadine Hydrochloride ophthalmic solution used for treatment of c...
- Lupin pharma gets USFDA nod to market ophthalmic solutionThe company said it has received the final approval for its product, a generic version of Allergan Inc's Lumigan Ophthalmic Solution, from ...
- Lupin launches generic ophthalmic solution in US marketLupin launched generic version of Allergan Inc's Zymaxid Ophthalmic Solution in US market with 180 days of marketing exclusivity.
Load More
